2013 FDA Drug Approval Calendar

BOSTON ( TheStreet) -- Gilead Sciences ( GILD) and Amarin ( AMRN) highlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.

The next era of hepatitis C therapy could begin on Dec. 6, if FDA approves Gilead's sofosbuvir. Amarin is hoping FDA approves an expanded label for its prescription-grade fish oil pill Vascepa on Dec. 20.

Sarepta Therapeutics ( SRPT) and Pharmacyclics ( PCYC) aren't on the list but are still very much in the investor spotlight. Sarepta and FDA are still going back and forth over the the company's request to file an accelerated approval application for eteplirsen to treat Duchenne muscular dystrophy. We may have some resolution early in the third quarter.

Pharmacylics and partner Johnson & Johnson ( JNJ) are expected to seek FDA approval for their blood-cancer drug ibrutinib before the end of the third quarter. FDA has already annointed ibrutinib with multiple breakthrough therapy designations, so it makes sense for the agency to approve the drug quickly. Is an ibrutinib approval before year end a possibility? I think so, in fact, I'd say the Street expects an early approval.

Let's not forget the importance of European drug approvals. Here are the dates for the remaining Committee for Medicinal Products for Human Use (CHMP) meetings in 2013:

May 27-30; June 24-27; July 22-25; Aug. 19-22; Sept. 16-19; Oct. 21-24; Nov. 18-2; and Dec. 16-19.

The most closely watched, upcoming European drug approval decisions include Dendreon ( DNDN) (Provenge, prostate cancer); Aegerion Pharmaceuticals ( AEGR) (Juxtapid, homozygous familial hypercholesterolemia) and Celgene ( CELG) (Pomalyst, multiple myeloma.)

Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst -- FDA drug approval decisions and advisory panels.

Merck ( MRK)
Drug/indication: Suvorexant for insomnia
FDA advisory panel: May 22
Approval decision date: June-July

Valeant Pharmaceuticals ( VRX)
Drug/indication: Efinaconazole, toe-nail fungus
Approval decision date: May 23

Depomed ( DEPO)
Drug/indication: Sefelsa, menopause
Approval decision date: May 31

Zogenix ( ZGNX)
Drug/indication: Zohydro, chronic pain
Approval decision date: Summer

GlaxoSmithKline ( GSK)
Drug/indication: Dabrafenib, melanoma
Approval decision date: June 3

Aveo Pharmaceuticals ( AVEO)
Drug/indication: Tivozanib, kidney cancer
Approval decision date: July 26

GlaxoSmithKline
Drug/indication: Dolutegravir, HIV
Approval decision date: Aug. 17

GlaxoSmithKline
Drug/indication: Trametenib, melanoma
Approval decision date: Sept. 3

Auxilium Pharmaceuticals ( AUXL)
Drug/indication: Xiaflex, Peyronie's Disease
Approval decision date: Sept. 6

Delcath Systems ( DCTH)
Drug/indication: Meblez, liver tumors due to ocular melanoma
Approval decision date: Sept. 13

Seattle Genetics ( SGEN)
Drug/indication: Adcetris, retreatment of Hodgkin's lymphoma
Approval decision date: Sept. 14

Antares Pharma ( ATRS)
Drug/indication: Otrexup, rheumatoid arthritis
Approval decision date: Oct. 14

Alimera Sciences ( ALIM), Psivida ( PSDV)
Drug/indication: Iluvien, diabetic macular edema
Approval decision date: Oct. 17

AMAG Pharmaceuticals ( AMAG)
Drug/indication: Feraheme, iron deficient anemia
Approval decision date: Oct. 21

Cubist Pharmaceuticals ( CBSST)
Drug/indication: Entereg, post-operative constipation
Approval decision date: Oct. 21

Gilead Sciences
Drug/indication: Sofosbuvir, hepatitis C
Approval decision date: Dec. 6

Amarin
Drug/indication: Vascepa, mixed dyslipidemia
Approval decision date: Dec. 20

Calendar compiled with assistance from BioMedTracker, company reports and TheStreet research.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Starbucks Stock Is Still Plunging

Starbucks Stock Is Still Plunging

Tesla Received Tip That Former Employee Was Going to 'Shoot the Place Up'

Tesla Received Tip That Former Employee Was Going to 'Shoot the Place Up'

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Jim Cramer: Williams Sonoma Is a Digitized Play

Jim Cramer: Williams Sonoma Is a Digitized Play

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers